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Background: Adherence rates for chronic pediatric conditions are approximately 50%. The primary objective of the study was to assess
rates of adherence using four different measurement methods for children with cystic fibrosis (CF).
Methods: Participants included 37 children with CF between 6 and 13 years of age and their primary caregivers. Adherence measures
included parent and child self-reports, diary data, pharmacy refill history, and electronic monitors.
Results: Results suggested that rates of adherence varied by treatment component and across measurement methods. However, when
examining more objective measures, rates of overall adherence were below 50% for children with CF, indicating generally poor adherence to
the treatment regimen. For example, rates of adherence to enzyme medications, using electronic and diary measures, ranged from 27% to
46%.
Conclusions: The multi-method measurement approach provided unique information regarding rates of adherence for each disease condition
by type of treatment component. Accurately measuring rates of treatment adherence for children with CF is an important step in developing
effective interventions to influence these behaviors.
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Medical treatments for chronic conditions, such as cystic
fibrosis (CF) can be burdensome, time-consuming, and
costly. Given the long-term and arduous nature of these
regimens, poor adherence is commonly reported, with
average rates of adherence generally below 50% [1].
Specifically, studies of children with CF have reported
adherence rates of 40–47% for chest physical therapy, a
form of airway clearance [2,3], while adherence to dietary
recommendations have been lower, ranging from 16% to
20% [3–5]. Two recent pediatric studies suggest that5 (2006) 177 – 185ed by Elsevier B.V. All rights reserved.
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[6,7], while the adult literature cites adherence rates between
24% and 82% [8]. However, these adherence estimates are
typically based on self-report measures or vial counts
(dornase alpha). New measurement methods and technolo-
gies are now available that may be used individually or in
combination to more reliably measure adherence behaviors.
In addition, little information is available on rates of
adherence for children to new medications, such as
nebulized antibiotics (e.g., tobramycin) or medications
critical to nutritional outcomes, such as pancreatic enzymes.
Lack of information regarding adherence makes it difficult
for physicians to determine the impact of these treatments
on health status or weigh the cost/benefit ratio for
prescribing these costly medications for their patients. Poor
adherence can have serious consequences, including in-
creased morbidity and mortality, reduced quality of life, and
greater health care costs [9–11]. Therefore, it is critically
important to accurately measure adherence in order to
identify and target factors that may positively influence
these behaviors. The purpose of the current study is to
document rates of adherence to medical regimens for CF
using four different measurement methods.
1.1. Measuring adherence
One reason for the wide range of adherence rates across
studies is the lack of a consistent measurement approach.
Several methods of assessment have been used, including
self-report, pharmacy refill data, diary methods, and
electronic monitoring [12–14]. However, each method has
its own strengths and weaknesses, suggesting a need for a
multi-method assessment of adherence [13,14]. To date, no
studies have documented rates of adherence using all four
methods in children with CF.
1.2. Self-report
Patient self-report is the most common adherence
measurement approach because it is practical and inexpen-
sive [1]. Burkhart and Dunbar-Jacob found that 71% of
studies examining pediatric adherence from 1987 to 1996
utilized self-report measures [15]. Of those studies, more
than one-third (36%) utilized self-report as the only
measure. However, self-reported adherence can be seriously
inflated. For example, research has documented 95%
adherence to inhaled corticosteroids for self-report versus
54% for electronic monitoring [16]. These studies highlight
the social desirability and recall biases that may be
associated with self-report, as well as the problems of
relying exclusively on this type of measurement.
1.3. Prescription refill history
Prescription refill histories are another useful method for
measuring adherence. Pharmacy databases provide infor-mation on the type and amount of medication that is
dispensed, as well as the dates of refills. However,
pharmacy data cannot determine whether the medications
were consumed or taken appropriately [12]. Further, they do
not capture samples dispensed at physician offices or
emergency rooms. Thus, this measure provides global
estimates of medication adherence that are useful for
identifying patients who clearly fail to refill prescriptions
[17,18]. To date, no studies have reported rates of adherence
for CF patients using pharmacy data.
1.4. Daily phone diary
Daily phone diary methods have also been used in
several studies of adherence [2,19,20]. The daily phone
diary (DPD) has been utilized with CF populations and has
demonstrated good reliability and validity [21]. The DPD
uses a cued recall procedure to track parents through their
activities over the past 24 h [21,22], eliciting information
about all activities lasting more than 5 min, including the
type of activity, its duration, companions, and a rating of
mood. Although diaries are a form of self-report, the
unobtrusive nature of the 24-h recall process (i.e., all
activities, not just adherence behaviors are reported) reduces
social desirability responding and its immediacy reduces
memory and recall problems. This potentially increases the
accuracy of the respondent’s report and its temporal
precision [2]. The disadvantages of the DPD method include
its time-intensive nature, the amount and complexity of the
data that is obtained, and its limited usefulness for younger
children [13]. Phone diary methods may be uniquely
beneficial in allowing researchers to gather information
about the processes related to poor disease management.
For example, phone diaries can reveal that a child missed
treatment because of a sports activity that occurred during
the usual treatment time [20]. Thus, the reasons underlying
poor adherence may be best identified through diary
methods.
1.5. Electronic monitoring
With the advent of new microchip technologies, elec-
tronic monitoring devices have now been developed to
assess a subset of adherence behaviors, including use of
metered dose inhalers (MDIs), opening pill bottles, and use
of nebulizer machines [23,24]. Several electronic monitor-
ing devices are available to measure adherence behaviors in
children with CF, including MEMS caps, MDI monitors,
and vest monitors. These monitoring devices allow for
precise recording of the date, time and duration of treat-
ments. They also allow for continuous, long-term measure-
ment that is unaffected by response biases [13]. Electronic
monitors can identify a variety of adherence problems,
including under- and over-use of medications, improper
technique in taking medications, delayed dosing, and drug
‘‘holidays’’ [1,13,14]. Unfortunately, as with all mechanical
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be lost. Furthermore, they are expensive and may not be
feasible for clinical use [1]. Although electronic monitors
have some limitations, as they are ‘‘debugged,’’ they may
become the future ‘‘gold standard’’ of adherence measure-
ment [25]. In the current study, convergence among these
four types of measures (e.g., self-report, prescription refill
data, daily diaries, and electronic monitoring) was com-
pared.
1.6. Current study
The first objective of this study was to document rates of
adherence to medical regimens for children with CF using
four methods of measurement. Rates of adherence to
different components of the regimen were expected to vary,
with average rates of adherence less than 50%. The second
objective was to assess convergence across the different
adherence measurement methods and identify the measure
that correlated most strongly with electronic monitoring.
Greatest concordance was expected between the diary
measure and electronic data as shown in a prior study [20].2. Materials and methods
2.1. Participants
Participants were recruited from two pediatric pulmonary
clinics in the southeastern United States. Eligibility criteria
included: 1) aged between 6 and 13 years, 2) a documented
diagnosis of CF by a physician for at least the prior year,
and 3) no major comorbid diagnoses (e.g., cerebral palsy,
cancer). Potential participants were mailed information
letters and brochures explaining the study. Participants were
then contacted by phone or during routine clinic visits to
review the study.
2.2. Procedure
The protocol and consent forms were approved by the
appropriate Institutional Review Boards/Human Research
Ethics Committee. Potential participants were identified
from the schedule of upcoming, routine clinic visits.
Participants were initially mailed information letters and
brochures explaining the study prior to their clinic visit and
then approached in clinic by a member of the research team
to answer questions about the study and obtain consent/
assent. After obtaining consent, primary caregivers and
children participated in a clinical interview with trained
graduate students or research assistants and then completed
several questionnaires, including a demographics form and
self-report measures of adherence (parents and children over
10 years of age). They were also scheduled to complete a
daily phone diary over 2 days prior to their next clinic visit
and utilize electronic monitors (e.g., MEMS cap) forenzymes over a 3-month period. Pharmacy refill history
was also collected at the end of the study for this 3-month
study period. In order to decrease social desirability
responding, participants were told that information from
the interviews would not be shared with the health care
team. Pulmonary function tests were also conducted to
assess the respiratory health status at each visit. Participants
were offered a $5 gift certificate to local stores for their
participation, $10 for completing daily phone diaries, and
$10 gift certificates for returning electronic monitors.
2.3. Measures
2.3.1. Background information form
Parents completed a Background Information Form at the
initial visit which asked about the child’s date of birth,
gender, parent’s age, socioeconomic status, occupation, and
composition of the family. Information about the child’s
medical history was also collected from the parent,
including date of diagnosis, presence of siblings with
chronic illnesses, and comorbid diagnoses.
2.3.2. Prescribed treatment plan
The Prescribed Treatment Plan (PTP) is a brief instru-
ment completed by physicians that documents the current
treatment regimen [13]. Each component of the child’s
regimen (e.g., medication, type, dosage, timing, method of
administration) is listed and is circled by the physician. The
PTP was completed at each clinic visit and took less than
2 min to complete.
2.3.3. Disease management interview
The Disease Management Interview-CF (DMI-CF) is a
51-item self-report measure of adherence for patients with
CF [13]. Before the interview, the challenges of managing
the child’s regimen were normalized for the family in order
to promote honest responding [26], using the following
statement ‘‘Most parents find it difficult to do all of the
treatments each day that are required for good CF care. We
are interested in knowing what you are currently doing with
your child for their care.’’ Parents were asked to consider the
disease management regimen completed over the past
2 weeks, with the exception of medications utilized on an
aperiodic basis, such as oral antibiotics and aerosolized
antibiotics. For these medications, parents were asked to
describe their use over the past 3 months.
For each component of the regimen, children (over 10
years of age) and parents were asked separately about the
frequency and duration of each treatment performed (e.g.,
chest physical therapy for 30 min, twice a day). Children
were shown pictures of possible medications to assist them
in reporting.
2.3.4. Prescription refill data
Consent to obtain prescription refill data from the
patient’s pharmacy was obtained at the initial visit. Each
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the 3-month period of the study. However, due to
implementation of new HIPPA guidelines, pharmacy refill
history could not be obtained for 49% of patients.
2.3.5. Daily phone diary (DPD)
The DPD uses a cued recall procedure to track parents
through their activities over the past 24 h [20–22]. For all
activities lasting 5 min or longer, mothers reported the type
of activity, duration, and who was present. The interviewer
initiated all phone calls and assisted each caregiver in
reconstructing their day as accurately as possible by
providing prompts, such as the time of day or information
about the previous activity (‘‘after you finished dinner, what
did you do next?’’). Each activity is recorded by the
interviewer on a computer screen with clock hands which
rotate through a 24-h clock, a set of activities, companions,
and a rating scale for mood ranging from 1 (Extremely
Negative) to 5 (Extremely Positive). A set of 2 DPDs (1
weekday and 1 weekend day) was conducted with the
primary caretaker by phone. The DPD procedure took
approximately 20–30 min to complete. The DPD has
yielded reliable stability coefficients over a 3-week period
(r values= .61–.71, p <.01) and high levels of interrater
reliability (>90%) in a CF population [27]. Furthermore,
strong convergent validity was found for parental differen-
tial treatment between the DPD and both home interview
and nightly rating scale measures for parents of toddlers [22]
and between daily routines and the Self Observation Report
Technique [28] (77–80% [27]). Overall, DPDs were
completed for 31 patients with CF.
2.3.6. Electronic monitoring/counter method
Electronic monitoring provides an ‘‘objective’’ method of
measuring adherence. However, due to the high costs of
these devices, only enzyme medications were monitored.
The Medication Event Monitoring Systems (MEMS\)
made by AARDEX Corporation was used to monitor
adherence to enzyme medications. It stores dates and times
for over 2000 doses. These data were downloaded to a
central docking station via computer when patients returned
the devices at the end of the study. Patients were asked to
bring their enzyme medications in for their next clinic
appointment and the medication was placed in the MEMS\
bottle with the cap. The MEMS\ cap did not account for the
number of capsules taken at each snack or meal; it was
assumed that patients extracted the correct number of
capsules.
2.3.7. Health status
Pulmonary function tests are the gold standard for
measuring respiratory functioning and lung damage for
patients with CF. Forced expiratory volume in one second
(FEV1 % predicted) is used as the primary indicator of
health status, using the Knudson equations for age, sex and
weight [29]. Illness severity ratings are based on establishedcutoffs for mild (>70%), moderate (40%<x <69%), and
severe (<39%) disease [30].
2.4. Statistical analyses
2.4.1. Calculating adherence scores
For each behavior that was monitored electronically, the
number of treatments performed each day divided by the
number of treatments prescribed was multiplied by 100 to
determine percent adherence (e.g., % of enzymes taken each
day). These percentages were calculated across the 3-month
time period. This procedure was used to calculate rates of
adherence from the self-report and diary measures. Trun-
cated adherence rates for each treatment component (e.g.,
maximum of 100%) were utilized to reduce inflation due to
overuse. This method has been utilized successfully in
studies assessing adherence with electronic monitoring [31].
Rates of adherence for several components of the child’s
treatment regimen (e.g., airway clearance, enzymes, inhaled
corticosteroids, nebulized medications) were calculated. In
addition, an overall adherence score was calculated across
all treatments for each child. Overall adherence was
calculated by summing all treatment adherence rates for
treatments and dividing this by the number of treatments
prescribed (e.g. 50% for enzymes, 100% for inhaled
tobramycin, 75% airway clearance, 50% vitamins; [(50+
100+75+50)/4=68.8%]). It is important to note that rates
of adherence could not be calculated for medications that
were PRN (e.g., as needed).
Prescription refill data was calculated for each medica-
tion prescribed. Rates of adherence for a single medication
taken continuously were calculated by dividing the medi-
cation obtained during a 3-month interval by the total
number of days in that interval (90 days). For example, if 30
days of medication were obtained over a period of 90 days,
the prescription refill rate was 33%.
Descriptive analyses, including means, medians, and
standard deviations, were calculated for rates of adherence
across the four methods of assessment for each component
of the treatment regimen and for overall adherence.
Wilcoxon Signed Ranks Tests were conducted to examine
convergence between the four measurement methods.
Significance was identified as p <.05.3. Results
3.1. Participants
Study participants included 37 children between the ages
of 6 and 13 with a primary diagnosis of CF and their
parents. Forty-three consecutive, potential participants were
eligible for the study. Six eligible participants were not
included for the following reasons: (a) five parents declined
to participate (e.g., too busy) and (b) one patient was
moving. No demographic or medical information was
Table 1
Rates of adherence for CF
Medication Parent self-report Child self report Diary Pharmacy refill history Electronic monitoring
Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.) Mean (S.D.)
Median Median Median Median Median
Sample size Sample size Sample size Sample size Sample size
Enzymes (n =36) 89.5 (21.7) 90.0 (25.5) 27.4 (22.9) 46.4 (32.5) 42.5 (32.4)
100 100 20 43.3 37.6
(n =36) (n =17) (n =31) (n =17) (n =27)
Airway clearance (n =36)
Frequency 74.4 (35.3) 66.9 (30.2) 51.1 (40.2)
100 100 50
(n =36) (n =17) (n =31)
Duration 73.5 (30.2) 69.4 (35.4) 64.2 (50.5)
75.0 75.0 75.0
(n =36) (n =17) (n =31)
Combined nebulized medicationsa (n =21) 82.4 (31.6) 80.0 (36.9) 47.6 (41.0) 68.3 (40.7)
100 100 50.0 100
(n =21) (n =10) (n =19) (n =11)
Dornase alpha (n =16) 90.4 (25.9) 77.8 (44.1) 56.7 (45.8) 71.7 (41.7)
100 100 50.0 100
(n =16) (n =9) (n =15) (n =11)
Inhaled tobramycin (n =10) 85. 0 (33.7) 83.3 (25.8) 36.1 (35.6)
100 100 25.0
(n =10) (n =6) (n =9)
Vitamins (n =34) 88.4 (27.6) 93.8 (17.1) 22.2 (34.2) 33.71(45.6)
100 100 0 0
(n =34) (n =16) (n =27) (n =14)
Adherence rates were not reported for measurement methods in which five or fewer participants provided data (e.g., nebulized bronchodilators).
a Combined nebulized medications included dornase alpha, inhaled tobramycin, and albuterol.
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new Health Insurance Portability and Accountability Act
(HIPAA) regulations, which limits access to patient health
information.
Twenty-six patients in the current study were part of a
larger, longitudinal adherence intervention trial funded by
the National Institutes of Health (NIH) [32]. Only self-report
data were available for four children because they had
begun an adherence intervention study, which could impact
their subsequent adherence scores over the 3-month studyFig. 1. Overall rates of adherence across tperiod. Thus, no data were included in analyses from
participants after they started the intervention.
Two children with CF dropped out of the study due to
busy schedules or family illness prior to the 3-month
assessment; however, self-report data were available for all
of these participants. No significant differences were found
between patients who dropped out of the study compared to
those who completed on the following variables: disease
severity, age, gender, parent-reported adherence or income
( p values=n.s.).reatments by measurement method.
1 Child self-reported adherence was not included due to small sample
size.
Fig. 2. Convergence for rates of adherence for enzymes (n =17). *Significantly different from other measurement methods ( p <.05).
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(S.D.=2.5), 49% were females and 89% were Caucasian,
3% African American, 3% Hispanic, and 5% Others.
Average FEV1 % predicted and FEF25–75 for the sample
was 79.6 (S.D.=20.8) and 72.2 (S.D.=32.8), respectively.
About 66% of the sample was classified as having mild
disease, 28% moderate disease, and 6% severe disease.
Median family income for the CF sample was $30,000–
49,999 US dollars, which is in the lower, middle income
bracket.
3.2. Rates of adherence for CF
Descriptive data regarding rates of adherence for CF are
presented in Table 1. For example, rates of adherence for
duration of airway clearance in CF ranged from 64% to 74%
depending on the measure. For nebulized medications,
which included a combination of nebulized bronchodilators
(e.g., Albuterol), dornase alpha, and inhaled tobramycin,
adherence rates ranged from 48% (diary) to 82% (parent
self-report). However, examination of specific nebulized
medications indicated that adherence rates ranged from 57%
to 90% for dornase alpha and from 36% to 85% for inhaled
tobramycin. Adherence for vitamins, which included
ADEK, multivitamins, and specific vitamins (e.g., Vitamin
K) was quite variable and ranged from 22% (diary data) to
94% (child self-report). Similarly, great variability in
adherence rates was found for enzymes, from 27% (diary
data) to 90% (child self-report).
Overall rates of adherence were calculated across all
treatments, with the exception of electronic monitoring
because it was only assessed for one treatment component
(e.g., enzymes) (see Fig. 1). As predicted, overall mean
rate of adherence for CF using objective measures (e.g.,
pharmacy refill history, diary data, and electronic moni-
toring) was below 50%. In comparison, self-reported
adherence by both parents and children was approximately
80%. These data confirmed the hypothesis that rates ofadherence, on average, would be less than 50% for
children with CF.
3.3. Convergence between measures of adherence
Because electronic monitoring was available for enzymes,
convergence between the measures was examined with this
particular medication. A subsample of patients, for whom
data was available across all four methods, was utilized in
these analyses.1 Pairwise comparisons of adherence rates
were conducted using a Wilcoxon Signed Ranks test. A
significant difference was found between parent-reported
adherence and more objective measures, with parents
reporting higher adherence rates compared to pharmacy refill
history, diary data, and electronic monitoring ( p values< .05)
(see Fig. 2).4. Discussion
Tremendous variability in rates of adherence was found
across measurement methods. Diary data indicated that
adherence to airway clearance was approximately 51% for
frequency and 64% for duration of treatment. These results
are better than those reported in other studies [2,3], which is
encouraging since this is a critically important aspect of
treatment for CF. In contrast, diary and electronic monitor-
ing data indicated poor adherence to enzymes (27%–43%),
which is a serious problem given the importance of nutrition
and weight gain for health outcomes in children with CF
[33]. Low adherence to pancreatic enzymes can result in
both short-term symptoms, such as gas, diarrhea, and
cramping, as well as long-term consequences, such as poor
growth and increased rates of pulmonary exacerbations [34].
In addition, low adherence was found for vitamins based on
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may be lacking the vitamins and minerals necessary for
optimal health. These data underscore the importance of
examining adherence to each treatment component. Future
intervention studies may want to emphasize the importance
of enzyme medications for children with CF, given the
positive relationship between good nutrition and mainte-
nance of lung functioning. Overall, these results suggest that
adherence to one component of treatment does not
necessarily equate to all components of the regimen.
When examining overall rates of adherence, significant
differences were found by measurement method. Self-
report measures substantially inflated rates of adherence,
whereas more objective measures (e.g. diary data, pharma-
cy refill history) revealed rates of adherence below 50% for
children with CF. Low rates of adherence in CF are most
likely due to the time-intensive, complex nature of the
regimen, with children in the current study completing
approximately seven treatments daily. Concerns about
adherence have spurred new efforts to reduce the time
and complexity of medical regimens for patients with
chronic illnesses. For example, dry powder formulations of
antibiotics and new nebulizers are in development which
can deliver medications in 2 to 5 min, instead of the usual
15 to 20 min.
A single, primary medication (e.g., enzymes) was used to
examine convergence between the four measures of
adherence, with electronic monitoring identified as the
‘‘gold’’ standard. Results indicated that both pharmacy refill
history and diary data were comparable to electronic
measures. Conversely, parent-reported adherence was mark-
edly inflated compared to these more objective measures.
These data indicated that in the absence of electronic data,
diaries and pharmacy refill history generally provide a good
estimate of adherence.
The multi-method measurement approach provided
unique information regarding rates of adherence by treat-
ment component. As in prior studies [13], parent and child
self-reported adherence was consistently higher than adher-
ence documented with other measurement methods. These
findings suggest that reporting biases and recall problems
may strongly influence self-report methods. For example,
parents may want to ‘‘please’’ their health care team by
appearing to follow the treatment regimen and they may
also have difficulty remembering exactly what treatments
they have performed. Physicians may also be reluctant to
probe patients/parents more deeply about their actual
adherence because it can jeopardize their patient–physician
relationship. Similar dilemmas face the healthcare team
collecting pharmacy records or electronic data in the context
of routine clinical care. In our experience, across several
large adherence trials [32,35], families have been willing to
accept both pharmacy data collection and electronic
monitoring in the context of research. However, before
implementing these measures in routine CF clinical care,
healthcare teams may want to openly discuss adherence andbarriers to effective disease management with patients and
family members [20]. Ideally, these discussions should be
part of every clinic visit to normalize difficulties with
adherence and to facilitate physician referrals to appropriate
specialists with training in behavioral techniques. To date,
little is known about how patients with CF would respond to
these discussions during routine clinic visits, however, in
other chronic conditions, such as diabetes, adherence
monitoring is part of standard clinical care (i.e., down-
loading of blood glucose meters) [36].
In this study, parents of children with CF reported rates
of adherence that were double of those obtained with
electronic monitors. Although self-report was inflated
compared to other measurement methods, good conver-
gence was found between parent and child reports of overall
adherence, suggesting that parents and children tend to
agree about the management of their treatment regimen.
One potentially important next step is to improve self-report
measures of adherence in the following ways: 1) Use more
supportive, non-judgmental language and reassure families
that the information is being utilized to help them better
manage the child’s disease, 2) Assess adherence over a
specific and reasonably short period of time (e.g., 1 week),
3) Provide anchors in the context of daily routines to
promote better recall of adherence behaviors (e.g., treat-
ments before or after school), 4) Conduct cognitive inter-
views with families to assess how they formulate their
estimates of adherence, and 5) Have frequent discussions
with healthcare providers to normalize the challenges
associated with managing complex, chronic diseases and
problem–solve the specific barriers encountered by that
family [37]. One promising finding is that the diary data in
this study, obtained in an unobtrusive manner, is a form of
self-report that provided more accurate rates of adherence
than more traditional paper–pencil self-report methods.
Although using a multi-method approach is often
recommended in the literature [1], it should be acknowl-
edged that it increases the complexity of both the analyses
and interpretation. Further, these methods often utilize
different time frames and yield different results, making it
difficult to obtain a unitary rate of adherence. Given the
infancy of adherence measurement in pediatric chronic
illness, the multimethod approach is still probably the best
one to use, despite its complexities [13]. Of the more
objective measurement methods, diary data in comparison
to electronic monitors offered the most comprehensive
method for measuring all of the components of the treatment
regimen. Electronic monitors are expensive and have
limitations, ranging from technical difficulties (e.g., mal-
functioning batteries) to being misplaced by patients. These
problems result in both the loss of valuable data and
expensive equipment.
Although this study presented an innovative method for
measuring adherence, several limitations were noted. First,
although the multi-method approach is ideal, as noted
earlier, different measurement methods use different time
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to 3-day period for diaries), making comparisons across
methods more difficult to interpret. Second, prescribed
treatment regimens for children with CF change frequently,
making it difficult to measure adherence over time. For
example, as children begin to experience symptoms of
infection or significant wheezing, physicians may prescribe
antibiotics or oral steroids for a brief period of time.
Measuring adherence to these critical, but short-term
medications is important, but often neglected in adherence
research. Another limitation was determining the prescribed
treatment regimen for patients due to poor documentation in
medical charts. Without a prescribed treatment plan, it is
nearly impossible to calculate rates of adherence for these
patients. Finally, it is important to note the statistical and
sample size limitations of the current study. Because each
child had a slightly different treatment regimen, the sample
sizes varied across measurement method. As a result,
descriptive analyses were utilized instead of formal statistics
in examining rates of adherence using the four measurement
methods. Although small samples are a common problem in
adherence research, the results of this study are quite similar
to those of other studies [6,35].
In summary, the results of this study highlight the need to
examine adherence by treatment component. Recent studies
have also begun to examine barriers to adherence by
treatment component to gain a better understanding of what
makes treatment difficult for families of children with
chronic illnesses [37]. Combined, these data will enable
healthcare teams to provide effective individualized inter-
ventions to improve adherence behaviors.Acknowledgements
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